Stemming Anginal Pain, Waiting for the Magic Cells.

The article focuses on the development of treatment modalities focused on end stage cardiovascular diseases. It mentions that the U.S. Food and Drug Administration approved the HeartMate II for destination therapy, as compared to transplantation. It focuses on the isolation of endothelial progenitor cells (EPC) from the peripheral circulation following granulocyte colony-stimulating factor (G-CSF) administration.